Introduction

 

Liver cancer is a well-known condition that is less common in the United States than in Africa and East Asia. Approximately 21,370 Americans will be diagnosed with liver cancer in 2008, according to the American Cancer Society. About 15,190 of those diagnosed will be men and 6,180 will be women. Nearly all people diagnosed with liver cancer are between the ages of 45 and 85, with the average age of 65.

The liver is a large internal organ that keeps you healthy by filtering dangerous substances out of your blood. It also makes enzymes (substances that speed up chemical changes), blood clotting factors, and bile, a substance that helps you digest food. Liver cancer is also called hepatic cancer. Hepatic is a medical term meaning “of or relating to the liver” (originating from the Greek “hepatikos”).

Cancer of the liver develops when liver cells grow and divide without stopping. The out-of-control liver cells form lumps (masses) called tumors. Liver tumors may develop as benign (noncancerous) growths that do not spread to other tissues or organs, or as malignant (cancerous) growths with cells that spread to other areas of the body and form new tumors.

Although the exact cause of liver cancer is not yet known, risk factors that increase the chances of developing this disease have been identified. Although not everyone with liver cancer has these risk factors, they include: being older; being male; having long-term inflammation (hepatitis) or scarring (cirrhosis) of the liver, or certain inherited metabolic diseases causing cirrhosis; drinking too much alcohol; taking anabolic steroids to build muscle strength; being exposed to toxic chemicals, such as aflatoxins, vinyl chloride, thorium dioxide, or arsenic; being very overweight; or having diabetes.

This content has been reviewed and approved by Myo Thant, MD.
This content was last modified on August 22, 2007 .
Latest Cancer News
ACOG Updates Cervical Cancer Screening Guidelines

November 20, 2009 — The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.

New Velcade®-melphalan Transplant Regimen for Multiple Myeloma

November 20, 2009 — Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient

November 20, 2009 — Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.

Select news items provided by Reuters Health